Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) had its target price boosted by analysts at Citigroup from $23.00 to $28.00 in a report issued on Friday, The Fly reports. Citigroup’s price target indicates a potential upside of 254.43% from the stock’s current price.
→ BREAKING: Tiny biotech successfully treats blindness (From Behind the Markets)
A number of other equities research analysts have also recently weighed in on ALDX. StockNews.com raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, November 14th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Aldeyra Therapeutics in a research note on Wednesday, March 1st.
Aldeyra Therapeutics Price Performance
Shares of ALDX stock opened at $7.90 on Friday. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $462.62 million, a P/E ratio of -7.12 and a beta of 1.07. Aldeyra Therapeutics has a 12 month low of $2.36 and a 12 month high of $7.99. The stock has a 50 day moving average of $6.65 and a two-hundred day moving average of $6.18.
Institutional Trading of Aldeyra Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC grew its position in shares of Aldeyra Therapeutics by 14.6% in the third quarter. Perceptive Advisors LLC now owns 11,350,085 shares of the biotechnology company’s stock valued at $60,609,000 after purchasing an additional 1,446,206 shares during the last quarter. Vanguard Group Inc. increased its holdings in Aldeyra Therapeutics by 5.2% in the first quarter. Vanguard Group Inc. now owns 2,961,635 shares of the biotechnology company’s stock valued at $13,165,000 after purchasing an additional 147,711 shares during the period. Verition Fund Management LLC grew its holdings in Aldeyra Therapeutics by 26.4% during the 3rd quarter. Verition Fund Management LLC now owns 2,402,239 shares of the biotechnology company’s stock worth $12,828,000 after acquiring an additional 501,048 shares during the period. Prosight Management LP grew its holdings in Aldeyra Therapeutics by 41.8% during the 2nd quarter. Prosight Management LP now owns 1,985,883 shares of the biotechnology company’s stock worth $7,924,000 after acquiring an additional 585,644 shares during the period. Finally, Knoll Capital Management LLC grew its holdings in Aldeyra Therapeutics by 24.9% during the 3rd quarter. Knoll Capital Management LLC now owns 1,877,305 shares of the biotechnology company’s stock worth $10,025,000 after acquiring an additional 374,845 shares during the period. Institutional investors and hedge funds own 63.11% of the company’s stock.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aldeyra Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aldeyra Therapeutics wasn’t on the list.
While Aldeyra Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
